These findings reveal that HOXB‐AS3/EZH2 complex–mediated Dicer suppression plays an important role in sorafenib resistance and cancer stemness and provide potential therapeutic strategies for diagnosing and treating liver cancer patients. Here, EZH2 is linked to liver cancer.